• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

    0.2500 -0.0267 (-9.65%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Mainz Biomed N.V. - Ordinary Shares

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening
    Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening 
    Via News Direct
    Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
    From Mainz BioMed NV
    Via GlobeNewswire
    What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer
    What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer 
    Via News Direct
    Exposures Product Safety
    Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
    From Mainz BioMed NV
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
    On Sunday, The Guardian issued an article that spoke of a UK study that could transform how cancer is treated. The large-scale clinical project assessed how personalized cancer therapies could... 
    Via Benzinga
    Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
    GANZIMMUN Diagnostics to Feature ColoAlert at the 57th Medizinische Woche Baden-Baden 
    From Mainz BioMed NV
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early
    Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early 
    Via News Direct
    The Covid Era Tech Promises To Reinvent Cancer Treatment
    Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story. 
    Via Benzinga
    Exposures COVID-19
    Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
    From Mainz BioMed NV
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Pfizer Advances On Its Cancer Journey
    On Saturday, Pfizer Inc (NYSE: PFE) presented positive trial data for experimental drug designed for patients suffering from cancer cachexia during the European Society for Medical Oncology 2024... 
    Via Benzinga
    Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
    Strategic Alliance with Former White House Senior Adviser to Focus on Awareness of Mainz Biomed’s Products and the Importance of Early Detection 
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool
    Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool 
    Via News Direct
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
    PancAlert is a Next-Generation Pancreatic Cancer Detection Test in Mainz Biomed’s Research and Development Pipeline – Promising Results of First Analysis 
    From Mainz BioMed NV
    Via GlobeNewswire
    Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test
    Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test 
    Via News Direct
    Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones
    Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones 
    Via News Direct
    Exposures Product Safety
    Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status
    Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status 
    Via News Direct
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
    The market for vaccines and treatments used in managing COVID-19 has shrunk by billions of dollars a year. Forced to rebuild their business, pharmaceutical companies like Pfizer Inc (NYSE: PFE)... 
    Via Benzinga
    Exposures COVID-19
    Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
    From Mainz BioMed NV
    Via GlobeNewswire
    Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
    This week, Pfizer Inc (NYSE: PFE) revealed a new collaboration to unlock new therapeutic approaches. Its smaller European industry peer specialized in early detection of cancer, Mainz Biomed N.V. 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
    It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Tuesday morning! 
    Via InvestorPlace
    Why Mainz Biomed Shares Are Trading Higher By Around 16%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
    From Mainz BioMed NV
    Via GlobeNewswire
    Why Arhaus Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    mRNA Technology Promises To Make A Long-Time Coming Turning Point In Cancer Treatment
    The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens... 
    Via Benzinga
    Exposures COVID-19
    Mainz Biomed Provides Half Year 2024 Corporate Update
    Industry Leading Clinical Data Position the Company for FDA Premarket Approval Study 
    From Mainz BioMed NV
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.